The latest results published by our AL Dose Impact Study Group confirm that the current recommended dose of artemether-lumefantrine (AL) – a leading antimalarial treatment – is still working very well in patients treated for malaria. However, the analyses of data from more than 14,000 patients also ...

Professor Chris Plowe, the longtime Head of the WWARN Molecular Group is busy with his new role as President of the American Society of Tropical Medicine and Hygiene in the USA.

The WWARN Network has initiated a series of pooled analyses of individual patient data to assess the risk factors associated with recurring malaria infection after treatment with the three main ACTs; artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP).

WWARN's Head of Drug Quality, Professor Paul Newton, and colleagues* published important recommendations in the British Medical Journal

A study published in The Lancet Infectious Diseases suggests that the spread of artemisinin drug resistance is following the same historical pathway as resistance to former frontline antimalarials